CZ306810B6
(cs)
*
|
1999-02-10 |
2017-07-19 |
Astrazeneca Ab |
Použití chinazolinového derivátu jako inhibitoru angiogeneze
|
CN100376567C
(zh)
|
1999-11-05 |
2008-03-26 |
阿斯特拉曾尼卡有限公司 |
作为vegf抑制剂的喹唑啉衍生物
|
WO2001066099A2
(en)
*
|
2000-03-06 |
2001-09-13 |
Astrazeneca Ab |
Use of quinazoline derivatives as angiogenesis inhibitors
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
EP1313727A1
(en)
*
|
2000-08-21 |
2003-05-28 |
AstraZeneca AB |
Quinazoline derivatives
|
JP2004511479A
(ja)
|
2000-10-13 |
2004-04-15 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
EP1326860A1
(en)
|
2000-10-13 |
2003-07-16 |
AstraZeneca AB |
Quinazoline derivatives
|
ATE399766T1
(de)
|
2000-10-20 |
2008-07-15 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische heterozyklen
|
AU2002217999A1
(en)
|
2000-11-01 |
2002-05-15 |
Cor Therapeutics, Inc. |
Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
|
DE60138645D1
(de)
|
2000-12-21 |
2009-06-18 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
*
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6995162B2
(en)
*
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
CA2441492C
(en)
*
|
2001-03-23 |
2011-08-09 |
Bayer Corporation |
Rho-kinase inhibitors
|
MY142915A
(en)
*
|
2001-03-23 |
2011-01-31 |
Bayer Healthcare Llc |
Rho-kinase inhibitors
|
US7141577B2
(en)
|
2001-04-19 |
2006-11-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1408980A4
(en)
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
NEW QUINAZOLINES AND THEIR USE
|
ES2272737T3
(es)
*
|
2001-07-16 |
2007-05-01 |
Astrazeneca Ab |
Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
|
GB0128109D0
(en)
*
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
KR101093345B1
(ko)
*
|
2002-02-01 |
2011-12-14 |
아스트라제네카 아베 |
퀴나졸린 화합물
|
ATE533750T1
(de)
|
2002-02-06 |
2011-12-15 |
Ube Industries |
Verfahren zur herstellung einer 4- aminochinazolinverbindung
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
WO2004004732A1
(en)
*
|
2002-07-09 |
2004-01-15 |
Astrazeneca Ab |
Quinazoline derivatives for use in the treatment of cancer
|
CA2491191C
(en)
|
2002-07-15 |
2014-02-04 |
Exelixis, Inc. |
Receptor-type kinase modulators and methods of use
|
TW200420542A
(en)
|
2002-08-23 |
2004-10-16 |
Kirin Brewery |
A compound having TGF β inhibition activity and a medicinal composition containing the same
|
RU2350618C2
(ru)
*
|
2002-11-04 |
2009-03-27 |
Астразенека Аб |
ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
|
EP1604665B1
(en)
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase inhibitor
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0310401D0
(en)
*
|
2003-05-07 |
2003-06-11 |
Astrazeneca Ab |
Therapeutic agent
|
GB0316127D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
GB0316123D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
GB0318422D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
PT1660090E
(pt)
*
|
2003-08-14 |
2013-01-11 |
Array Biopharma Inc |
Análogos de quinazolina como inibidores de tirosina-cinases recetoras
|
ES2925655T3
(es)
|
2003-09-26 |
2022-10-19 |
Exelixis Inc |
Moduladores c-Met y métodos de uso
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
GB0328040D0
(en)
*
|
2003-12-03 |
2004-01-07 |
Coleman Robert E |
Pharmaceutical uses of bisphosphonates
|
GEP20084572B
(en)
|
2003-12-23 |
2008-12-25 |
Pfizer |
Novel quinoline derivatives
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1711495A2
(en)
*
|
2004-01-23 |
2006-10-18 |
Amgen Inc. |
Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
|
AU2005206571B8
(en)
*
|
2004-01-23 |
2010-09-02 |
Amgen Inc. |
Compounds and methods of use
|
CA2558346A1
(en)
*
|
2004-03-23 |
2005-10-06 |
Astrazeneca Ab |
Combination therapy
|
GB0406446D0
(en)
*
|
2004-03-23 |
2004-04-28 |
Astrazeneca Ab |
Combination therapy
|
GB0406445D0
(en)
*
|
2004-03-23 |
2004-04-28 |
Astrazeneca Ab |
Combination therapy
|
WO2005113494A2
(en)
|
2004-05-07 |
2005-12-01 |
Amgen Inc. |
Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
|
WO2006030941A1
(ja)
|
2004-09-13 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
スルホンアミド含有化合物の血管新生阻害物質との併用
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
AR050948A1
(es)
|
2004-09-24 |
2006-12-06 |
Hoffmann La Roche |
Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
|
WO2006035203A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Astrazeneca Ab |
Cancer combination therapy comprising azd2171 and imatinib
|
ATE540935T1
(de)
|
2004-10-12 |
2012-01-15 |
Astrazeneca Ab |
Chinazolinderivate
|
EP1827434B1
(en)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
KR101017301B1
(ko)
|
2004-12-21 |
2011-02-28 |
메드임뮨 리미티드 |
앤지오포이에틴-2에 대한 항체 및 그의 용도
|
EP1674467A1
(en)
*
|
2004-12-22 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
|
EP1879894A1
(en)
|
2005-04-14 |
2008-01-23 |
F.Hoffmann-La Roche Ag |
Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
US8299076B2
(en)
|
2005-05-18 |
2012-10-30 |
Array Biopharma Inc. |
Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
|
AU2006265835B2
(en)
*
|
2005-06-30 |
2012-05-03 |
Amgen Inc. |
Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
|
WO2007015569A1
(ja)
*
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
CN102716490A
(zh)
*
|
2005-09-01 |
2012-10-10 |
卫材R&D管理有限公司 |
药物组合物的崩解性的改善方法
|
US8247556B2
(en)
|
2005-10-21 |
2012-08-21 |
Amgen Inc. |
Method for preparing 6-substituted-7-aza-indoles
|
AU2006309551B2
(en)
*
|
2005-11-07 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
WO2007061130A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
GB0523810D0
(en)
|
2005-11-23 |
2006-01-04 |
Astrazeneca Ab |
Pharmaceutical compositions
|
WO2007071970A2
(en)
*
|
2005-12-22 |
2007-06-28 |
Astrazeneca Ab |
Combination of azd2171 and pemetrexed
|
US7868177B2
(en)
|
2006-02-24 |
2011-01-11 |
Amgen Inc. |
Multi-cyclic compounds and method of use
|
EP1991531A1
(en)
*
|
2006-02-28 |
2008-11-19 |
Amgen Inc. |
Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
|
UY30183A1
(es)
*
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
EP1994024A2
(en)
*
|
2006-03-02 |
2008-11-26 |
AstraZeneca AB |
Quinoline derivatives
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2036557B1
(en)
*
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
MX2009001946A
(es)
|
2006-08-23 |
2009-03-05 |
Kudos Pharm Ltd |
Derivados de 2-metilmorfolin-pirido-, pirazo- y pirimido- pirimidina como inhibidores de mtor.
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
EP2061469B8
(en)
|
2006-09-11 |
2014-02-26 |
Curis, Inc. |
Quinazoline based egfr inhibitors
|
AU2012204077B2
(en)
*
|
2006-11-02 |
2012-11-29 |
Astrazeneca Ab |
Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
|
US7851623B2
(en)
|
2006-11-02 |
2010-12-14 |
Astrazeneca Ab |
Chemical process
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
MX2009006543A
(es)
|
2006-12-20 |
2009-06-26 |
Amgen Inc |
Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
JP5377332B2
(ja)
|
2007-02-06 |
2013-12-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
US8148532B2
(en)
|
2007-03-14 |
2012-04-03 |
Guoqing Paul Chen |
Spiro substituted compounds as angiogenesis inhibitors
|
TW200902018A
(en)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
WO2008125820A1
(en)
*
|
2007-04-13 |
2008-10-23 |
Astrazeneca Ab |
Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
|
RU2455994C2
(ru)
|
2007-04-16 |
2012-07-20 |
Хатчисон Медифарма Энтерпрайзис Лимитед |
Пиримидиновые производные
|
WO2009030224A2
(de)
*
|
2007-09-07 |
2009-03-12 |
Schebo Biotech Ag |
Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
|
TW200922590A
(en)
*
|
2007-09-10 |
2009-06-01 |
Curis Inc |
VEGFR inhibitors containing a zinc binding moiety
|
AU2008299896B2
(en)
|
2007-09-10 |
2012-02-02 |
Curis, Inc. |
Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
US8119616B2
(en)
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
NZ585261A
(en)
|
2007-10-11 |
2011-10-28 |
Astrazeneca Ab |
Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
|
AU2008319366B2
(en)
*
|
2007-10-29 |
2012-03-01 |
Amgen Inc. |
Benzomorpholine derivatives and methods of use
|
AU2008325608B2
(en)
|
2007-11-09 |
2013-03-14 |
Eisai R & D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
PE20091158A1
(es)
|
2007-12-19 |
2009-08-28 |
Genentech Inc |
5-anilinoimidazopiridinas y metodos de uso
|
KR20100099185A
(ko)
|
2007-12-21 |
2010-09-10 |
제넨테크, 인크. |
아자인돌리진 및 이용 방법
|
CN101215274B
(zh)
*
|
2007-12-27 |
2011-05-04 |
上海北卡医药技术有限公司 |
N取代吗啉类有机化合物的制备工艺
|
EP2247579B1
(en)
*
|
2008-01-17 |
2012-04-18 |
Bayer Pharma Aktiengesellschaft |
Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments
|
WO2009094211A1
(en)
*
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Quinazoline compounds and methods of treating cancer
|
EP2248804A4
(en)
*
|
2008-01-29 |
2014-09-10 |
Eisai R&D Man Co Ltd |
COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
|
EA019709B1
(ru)
|
2008-02-07 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Спирогетероциклы и их применение в качестве лекарственных средств
|
BRPI0908100A2
(pt)
*
|
2008-02-21 |
2015-10-06 |
Astrazeneca Ab |
produto combinação, uso de um composto, e, método de tratar câncer
|
EP2474323A3
(en)
*
|
2008-03-26 |
2012-10-10 |
Novartis AG |
Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
|
US7829574B2
(en)
*
|
2008-05-09 |
2010-11-09 |
Hutchison Medipharma Enterprises Limited |
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
|
CA2723989C
(en)
|
2008-05-13 |
2017-04-25 |
Astrazeneca Ab |
Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
|
US8426430B2
(en)
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
EP2149565A1
(de)
*
|
2008-07-24 |
2010-02-03 |
Bayer Schering Pharma AG |
Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
US8211911B2
(en)
|
2008-08-19 |
2012-07-03 |
Guoqing Paul Chen |
Compounds as kinase inhibitors
|
TW201008933A
(en)
|
2008-08-29 |
2010-03-01 |
Hutchison Medipharma Entpr Ltd |
Pyrimidine compounds
|
EP2344536A1
(en)
|
2008-09-19 |
2011-07-20 |
MedImmune, LLC |
Antibodies directed to dll4 and uses thereof
|
RU2011119478A
(ru)
*
|
2008-10-14 |
2012-11-27 |
Нин Си |
Соединения и способы применения
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
TWI447108B
(zh)
|
2009-01-16 |
2014-08-01 |
Exelixis Inc |
N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型
|
AU2010210646B2
(en)
|
2009-02-05 |
2015-10-29 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
KR20110113755A
(ko)
|
2009-02-10 |
2011-10-18 |
아스트라제네카 아베 |
트리아졸로 〔4,3-b〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
|
CA2755061A1
(en)
|
2009-03-13 |
2010-09-16 |
Cellzome Limited |
Pyrimidine derivatives as mtor inhibitors
|
IT1393351B1
(it)
*
|
2009-03-16 |
2012-04-20 |
Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa |
Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
|
AU2010229147B2
(en)
*
|
2009-03-21 |
2012-07-05 |
Sunshine Lake Pharma Co., Ltd. |
Amino ester derivatives, salts thereof and methods of use
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
CA2758614A1
(en)
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
US20120172385A1
(en)
|
2009-09-11 |
2012-07-05 |
Richard John Harrison |
Ortho substituted pyrimidine compounds as jak inhibitors
|
AU2010309882B2
(en)
|
2009-10-20 |
2016-01-28 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
CA2777746C
(en)
|
2009-11-18 |
2019-05-14 |
Astrazeneca Ab |
Benzoimidazole compounds and uses thereof
|
BR122021025338B1
(pt)
|
2009-11-24 |
2023-03-14 |
Medimmune Limited |
Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
EP2519517B1
(en)
*
|
2009-12-29 |
2015-03-25 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
EP3296313B1
(en)
|
2010-01-15 |
2020-12-16 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
US8198285B2
(en)
|
2010-01-19 |
2012-06-12 |
Astrazeneca Ab |
Pyrazine derivatives
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
US9249129B2
(en)
|
2010-03-04 |
2016-02-02 |
Cellzome Limited |
Morpholino substituted urea derivatives as mTOR inhibitors
|
BR112012027803A2
(pt)
|
2010-04-30 |
2016-08-09 |
Cellzome Ltd |
compostos de pirazol como inibidores de jak
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
EP2588105A1
(en)
|
2010-07-01 |
2013-05-08 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
US9040545B2
(en)
|
2010-08-20 |
2015-05-26 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
CN103298794A
(zh)
|
2010-11-09 |
2013-09-11 |
塞尔卓姆有限公司 |
作为tyk2抑制剂的吡啶化合物及其氮杂类似物
|
EP2640716A1
(en)
|
2010-11-19 |
2013-09-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
CN103619865B
(zh)
|
2011-02-02 |
2016-10-12 |
苏州润新生物科技有限公司 |
某些化学个体、组合物及方法
|
SI2675479T1
(sl)
|
2011-02-15 |
2016-04-29 |
Immunogen, Inc. |
Citotoksični derivati benzodiazepina
|
WO2012110773A1
(en)
|
2011-02-17 |
2012-08-23 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
DK2675794T3
(da)
|
2011-02-17 |
2019-05-06 |
Cancer Therapeutics Crc Pty Ltd |
Selektive fak-inhibitorer
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
US20140163023A1
(en)
|
2011-04-04 |
2014-06-12 |
Cellzome Limited |
Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
RU2580609C2
(ru)
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
ES2705950T3
(es)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
EP4086246A1
(en)
|
2011-07-27 |
2022-11-09 |
AstraZeneca AB |
2-(2,4,5-substituted-anilino)pyrimidine compounds as egfr modulators
|
AU2012288892B2
(en)
|
2011-07-28 |
2016-04-21 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as JAK inhibitors
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
JP6002223B2
(ja)
|
2011-08-26 |
2016-10-05 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
EP2753174A4
(en)
|
2011-09-01 |
2015-05-20 |
Xiangping Qian |
PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
|
US9518029B2
(en)
|
2011-09-14 |
2016-12-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
RU2014115476A
(ru)
|
2011-09-20 |
2015-10-27 |
Целльзом Лимитед |
Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ
|
AU2012311458B2
(en)
|
2011-09-21 |
2016-02-04 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mTOR inhibitors
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
EP2760458B1
(en)
|
2011-09-29 |
2017-06-14 |
The University of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
ES2592219T3
(es)
|
2011-10-07 |
2016-11-28 |
Cellzome Limited |
Derivados de {(4-(4-morfolino-dihidrotieno[3,4-d]pirimidin-2-il)aril}urea o carbamato como inhibidores de mTOR
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
RU2014130214A
(ru)
|
2011-12-23 |
2016-02-10 |
Целльзом Лимитид |
Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
|
EP2806874B1
(en)
|
2012-01-25 |
2017-11-15 |
Neupharma, Inc. |
Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
CN109354598A
(zh)
|
2012-04-29 |
2019-02-19 |
润新生物公司 |
化学个体、药物组合物及癌症治疗方法
|
JP6498600B2
(ja)
|
2012-06-08 |
2019-04-10 |
ストロ バイオファーマ インコーポレーテッド |
部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
US9238644B2
(en)
|
2012-08-17 |
2016-01-19 |
Cancer Therapeutics Crc Pty Limited |
VEGFR3 inhibitors
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
CN104981254B
(zh)
|
2012-08-31 |
2018-05-22 |
苏特罗生物制药公司 |
含有叠氮基的经修饰的氨基酸
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
US9688635B2
(en)
|
2012-09-24 |
2017-06-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
JP6277198B2
(ja)
|
2012-11-05 |
2018-02-07 |
ナント ホールディングス アイピー,エルエルシー |
置換インドール−5−オール誘導体及びそれらの治療適用
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
EP2937337A4
(en)
|
2012-12-21 |
2016-06-22 |
Eisai R&D Man Co Ltd |
AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
|
PT2951177T
(pt)
|
2013-01-31 |
2018-05-23 |
Neomed Inst |
Compostos imidazopiridina e suas utilizações
|
AU2014216178B2
(en)
|
2013-02-15 |
2018-06-28 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
CN105189462B
(zh)
*
|
2013-02-20 |
2017-11-10 |
卡拉制药公司 |
治疗性化合物和其用途
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
EP2961435B1
(en)
|
2013-02-28 |
2019-05-01 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9999680B2
(en)
|
2013-02-28 |
2018-06-19 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
|
RS57569B1
(sr)
|
2013-03-13 |
2018-10-31 |
Abbvie Inc |
Postupci za pripremanje agensa koji uzrokuje apoptozu
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
US9550760B2
(en)
|
2013-03-15 |
2017-01-24 |
Nantbioscience, Inc. |
Substituted indol-5-ol derivatives and their therapeutic applications
|
CN105142648A
(zh)
|
2013-03-15 |
2015-12-09 |
玛格塞蒂克斯公司 |
用于癌症的镁组合物及其用途
|
CN104334543B
(zh)
*
|
2013-04-09 |
2017-08-25 |
广州慧柏瑞生物医药科技有限公司 |
抗新生血管的化合物、其中间体及其用途
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
EP2806480B1
(en)
*
|
2013-05-20 |
2017-08-09 |
Nintendo Co., Ltd. |
Battery accomodation structure and battery accomodation method
|
CN103275069B
(zh)
*
|
2013-05-22 |
2015-03-11 |
苏州明锐医药科技有限公司 |
西地尼布的制备方法
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3004073A1
(en)
|
2013-06-07 |
2016-04-13 |
Université catholique de Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
MX369863B
(es)
|
2013-08-23 |
2019-11-25 |
Neupharma Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
CN103509005B
(zh)
*
|
2013-09-26 |
2015-04-08 |
苏州海特比奥生物技术有限公司 |
喹唑啉类化合物及其制备方法与应用
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP2868702A1
(en)
|
2013-10-29 |
2015-05-06 |
DyStar Colours Distribution GmbH |
Disperse dyes, their preparation and their use
|
EP3062795A4
(en)
*
|
2013-11-01 |
2017-05-31 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CN106061261B
(zh)
*
|
2013-11-01 |
2018-04-24 |
卡拉制药公司 |
治疗化合物的结晶形式及其用途
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
TWI721954B
(zh)
|
2014-08-28 |
2021-03-21 |
日商衛材R&D企管股份有限公司 |
高純度喹啉衍生物及其生產方法
|
CN105461698A
(zh)
*
|
2014-09-12 |
2016-04-06 |
杭州普晒医药科技有限公司 |
西地尼布盐及其晶型、以及其制备方法和药物组合物
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
WO2016133935A1
(en)
|
2015-02-17 |
2016-08-25 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
RU2017128583A
(ru)
|
2015-02-25 |
2019-03-25 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Способ ослабления горечи хинолинового производного
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
CN113336746A
(zh)
|
2015-08-04 |
2021-09-03 |
常州千红生化制药股份有限公司 |
N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
|
BR112018006873A2
(pt)
|
2015-10-05 |
2018-11-06 |
The Trustees Of Columbia University In The City Of New York |
ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
|
MX2018009085A
(es)
|
2016-01-27 |
2019-05-09 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
|
AU2017221268B2
(en)
|
2016-02-15 |
2024-02-15 |
Astrazeneca Ab |
Methods comprising fixed intermittent dosing of cediranib
|
SI3442535T1
(sl)
|
2016-04-15 |
2023-01-31 |
Cancer Research Technology Limited |
Heterociklične spojine kot zaviralci RET-kinaze
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
EP3497087B1
(en)
|
2016-08-15 |
2021-11-10 |
Neupharma, Inc. |
Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
|
EP3507305A1
(en)
|
2016-09-02 |
2019-07-10 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
CA3036340A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CA3036336A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
MX2019002629A
(es)
|
2016-09-08 |
2019-10-07 |
Kala Pharmaceuticals Inc |
Formas cristalinas de compuestos terapéuticos y usos de los mismos.
|
JP7118974B2
(ja)
|
2016-09-22 |
2022-08-16 |
キャンサー・リサーチ・テクノロジー・リミテッド |
ピリミジノン誘導体の調製および使用
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
JP6755775B2
(ja)
*
|
2016-11-04 |
2020-09-16 |
富士アミドケミカル株式会社 |
4−フルオロイソキノリンの製法
|
US11306070B2
(en)
|
2016-11-22 |
2022-04-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
EP3548478B1
(en)
|
2016-12-05 |
2021-11-17 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
CN106831729A
(zh)
*
|
2016-12-19 |
2017-06-13 |
浙江工业大学 |
一种西地尼布的纯化方法
|
US11111245B2
(en)
|
2017-02-01 |
2021-09-07 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
WO2018215798A1
(en)
|
2017-05-26 |
2018-11-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
CN111163839B
(zh)
|
2017-05-26 |
2024-05-28 |
癌症研究科技有限公司 |
苯并咪唑酮衍生的bcl6抑制剂
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
CN111278840B
(zh)
|
2017-08-18 |
2023-11-17 |
癌症研究科技有限公司 |
吡咯并[2,3-b]吡啶化合物及其治疗癌症的用途
|
BR112020005212A2
(pt)
|
2017-09-18 |
2020-09-15 |
Sutro Biopharma, Inc. |
conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
|
BR112020007787A2
(pt)
*
|
2017-10-20 |
2020-10-06 |
Kala Pharmaceuticals, Inc. |
inibidores ret9 e vegfr2
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
CN111757881B
(zh)
|
2018-01-15 |
2024-05-07 |
澳升医药公司 |
作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
WO2019157225A2
(en)
|
2018-02-08 |
2019-08-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
AU2019253510B2
(en)
|
2018-04-13 |
2023-08-10 |
Cancer Research Technology Limited |
BCL6 inhibitors
|
FR3080620B1
(fr)
*
|
2018-04-27 |
2021-11-12 |
Univ Paris Sud |
Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
|
CN112513031A
(zh)
|
2018-06-04 |
2021-03-16 |
阿普罗斯治疗公司 |
可用于治疗与tlr7调节相关的疾病的含酸性基团的嘧啶化合物
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
WO2020057403A1
(zh)
*
|
2018-09-18 |
2020-03-26 |
北京越之康泰生物医药科技有限公司 |
吲哚衍生物及其在医药上的应用
|
AU2019346550A1
(en)
|
2018-09-25 |
2021-04-22 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
CN111747931A
(zh)
|
2019-03-29 |
2020-10-09 |
深圳福沃药业有限公司 |
用于治疗癌症的氮杂芳环酰胺衍生物
|
JP2022528562A
(ja)
|
2019-04-05 |
2022-06-14 |
ストーム・セラピューティクス・リミテッド |
Mettl3阻害化合物
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
CA3152674A1
(en)
|
2019-08-31 |
2021-03-04 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole derivatives for fgfr inhibitor and preparation method thereof
|
CA3147493A1
(en)
|
2019-09-20 |
2021-03-25 |
Jr. James Clifford Sutton |
4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
EP4069694A1
(en)
|
2019-12-02 |
2022-10-12 |
Storm Therapeutics Ltd |
Polyheterocyclic compounds as mettl3 inhibitors
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
US20230391770A1
(en)
|
2020-10-06 |
2023-12-07 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
WO2022074391A1
(en)
|
2020-10-08 |
2022-04-14 |
Storm Therapeutics Limited |
Compounds inhibitors of mettl3
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
CA3220146A1
(en)
|
2021-05-17 |
2022-11-24 |
Hk Inno.N Corporation |
Benzamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing of treating cancer containing the same as an active ingredient
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
CA3237696A1
(en)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023161881A1
(en)
*
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024003241A1
(en)
|
2022-06-30 |
2024-01-04 |
Astrazeneca Ab |
Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
|
WO2024006542A1
(en)
|
2022-06-30 |
2024-01-04 |
Sutro Biopharma, Inc. |
Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024059169A1
(en)
*
|
2022-09-14 |
2024-03-21 |
Blueprint Medicines Corporation |
Egfr inhibitors
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|